Drug intelligence / Profile preview

NuDYN

Development stage: Phase 4
Lead developer: Fidia Farmaceutici
Administration: Intraarticular, Intralesional

Overview

NuDYN is a shelf-stable, injectable, flowable amniotic membrane-derived allograft developed by Fidia Pharma USA Inc. for the treatment of musculoskeletal and orthopedic conditions. Derived from donated human placentas via cesarean delivery, the product is processed to be acellular while retaining intrinsic biological components such as hyaluronic acid, collagen, and various growth factors. It is regulated by the FDA as a human cell, tissue, and cellular and tissue-based product (HCT/P) under Section 361 of the Public Health Service Act. NuDYN is primarily utilized in non-surgical applications to support the health of cartilage, tendons, ligaments, and soft tissues, and is available by prescription in 1 mL and 2 mL vials.

Brand names: NuDYN
Other names: amniotic membrane-derived allograft

Beyond the preview

Go deeper on NuDYN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuDYN.

Explore the full profile